A kidney cancer drug from Aveo Pharmaceuticals (AVEO) outperformed an approved drug from Onyx Pharmaceuticals (ONXX) in a late-stage study comparing the two treatments head-to-head. Based on these data, the firm says it plans to submit for marketing approval of tivozanib in the United States and Europe this year.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs